Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
GSK plummets as US restricts RSV vaccine
03:40am, Thursday, 27'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) is attempting to drive the FTSE 100 lower after it plunged close to 7% following a ruling in the US that restricted the use of its RSV vaccine. The US Advisor Committee on
GSK slides 6% after US CDC narrows scope of RSV shots
03:40am, Thursday, 27'th Jun 2024
GSK's shares dropped more than 6% on Thursday, a day after a U.S. public health agency narrowed its usage recommendation for all respiratory syncytial virus (RSV) vaccines and held off on recommending
Vaccine makers' stocks fall as CDC advisers shift RSV-shot recommendations
04:29pm, Wednesday, 26'th Jun 2024
Shares of vaccine makers Pfizer Inc., GSK PLC and Moderna Inc. dropped Wednesday as advisers to the Centers for Disease Control and Prevention shifted their recommendations for who should be vaccinate
US advisers to consider RSV shots as GSK looks to keep market lead
06:13am, Wednesday, 26'th Jun 2024
A committee of outside experts to the U.S. CDC are set to vote on whether to expand the age group of adults who should receive respiratory syncytial virus (RSV) vaccines this year, as GSK battles riva
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
10:40am, Monday, 24'th Jun 2024
The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.
Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names
09:55am, Monday, 24'th Jun 2024
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
GSK 100% backs London listing, says boss
05:02am, Friday, 21'st Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) has issued its support to the flagging London market, stating that it is “unequivocally, 100 per cent committed” to keeping its listing in the UK. Speaking at the Time
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
01:44pm, Tuesday, 18'th Jun 2024
Cantor Fitzgerald has initiated coverage on Innoviva, Inc. INVA, citing the company's unique business model centered around royalties and healthcare assets.
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
GSK Enters Into a Multi-Year Data Licence Agreement With Ochre Bio to Further Investigate the Drivers of Liver Disease
07:00am, Wednesday, 12'th Jun 2024
OXFORD, England--(BUSINESS WIRE)--Ochre Bio, a pioneer in chronic liver disease medicine development, has today announced the start of a multi-year data licence agreement with GSK. The partnership wil
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:45am, Tuesday, 11'th Jun 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK 'still appealing' despite US legal setback says broker
04:33am, Tuesday, 11'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) is 'still appealing' - even in the wake of a significant legal setback, according to regional broker Shore Capital, which set out its 'buy' case in the wake of the UK drug
GSK appeals Delaware Zantac ruling
03:16am, Tuesday, 11'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) and other pharmaceutical companies asked a Delaware court to allow an appeal of a ruling permitting over 70,000 lawsuits claiming Zantac causes cancer. Analysts had expec
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
09:55am, Monday, 10'th Jun 2024
GSK's Arexvy becomes the first RSV vaccine approved for adults aged 50-59 who are at high risk.
GSK RSV jab receives label expansion from US regulator
03:16am, Monday, 10'th Jun 2024
GSK PLC (LSE:GSK, NYSE:GSK) has confirmed that the US Food & Drug Administration has approved Arexvy for preventing respiratory syncytial virus (RSV) in adults aged 50 to 59 at increased risk of sever
